Your browser doesn't support javascript.
loading
Evaluation of the total distribution volume of 18F-FBPA in normal tissues of healthy volunteers by non-compartmental kinetic modeling.
Romanov, Victor; Isohashi, Kayako; Alobthani, Galal; Beshr, Rouaa; Horitsugi, Genki; Kanai, Yasukazu; Naka, Sadahiro; Watabe, Tadashi; Shimosegawa, Eku; Hatazawa, Jun.
Afiliación
  • Romanov V; Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Yamada Oka 2-2, Suita, Osaka, 565-0871, Japan.
  • Isohashi K; Immunology Frontier Research Center, Osaka University, Suita, Japan.
  • Alobthani G; Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Yamada Oka 2-2, Suita, Osaka, 565-0871, Japan.
  • Beshr R; Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Yamada Oka 2-2, Suita, Osaka, 565-0871, Japan.
  • Horitsugi G; Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Yamada Oka 2-2, Suita, Osaka, 565-0871, Japan.
  • Kanai Y; Immunology Frontier Research Center, Osaka University, Suita, Japan.
  • Naka S; Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Yamada Oka 2-2, Suita, Osaka, 565-0871, Japan.
  • Watabe T; Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Yamada Oka 2-2, Suita, Osaka, 565-0871, Japan.
  • Shimosegawa E; Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Yamada Oka 2-2, Suita, Osaka, 565-0871, Japan.
  • Hatazawa J; Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Yamada Oka 2-2, Suita, Osaka, 565-0871, Japan.
Ann Nucl Med ; 34(3): 155-162, 2020 Mar.
Article en En | MEDLINE | ID: mdl-31808134
ABSTRACT

OBJECTIVE:

Boron neutron capture therapy (BNCT) is a noninvasive radiation therapy method for cancer treatment. In BNCT, 4-borono-2-[18F]-fluoro-L-phenylalanine (18F-FBPA) PET has been employed to estimate 10B accumulation in target tumors and normal tissues if 10B borono-L-phenylalanine (10B-BPA) is used as a boron carrier. The purpose of the current study was to evaluate the total distribution volume (Vt) of 18F-FBPA in normal organs of healthy volunteers by kinetic analysis and to estimate boron concentration in normal organs for the therapeutic dose of 10B-BPA using obtained Vt values.

METHODS:

Six healthy volunteers were injected with 18F-FBPA (3-5 MBq/kg), and 7 PET-CT scans were performed subsequently. 18F-FBPA radioactivity in whole blood and plasma was measured before, and eight times after the injection. PET images were analyzed by PMOD software. Twelve volumetric regions of interest including the brain, heart, right lung, spleen, liver, parotid salivary glands, esophagus, stomach, pancreas, intestines, and bone marrow were drawn manually for each subject and analyzed with the Logan plot and two Ichise multilinear analyses (MA1 and MA2). The better model was defined by several goodness-of-fit parameters and residual distribution. After Vt values had been derived, boron concentration was estimated in ppm for the 10B-BPA-fructose (10B-BPA-fr) dose 30 g 1 and 2 h post-injection using Vt and interpolated plasma activity data.

RESULTS:

The Ichise MA2 model showed the best fit among all models. Akaike Information Criterion (AIC) was the lowest for the Ichise's MA2 in all regions (mean AIC value - 14.0) comparing to the other models (Logan plot mean AIC 31.4; Ichise MA1 model mean AIC - 4.2). Mean Vt values of the Ichise MA2 model ranged from 0.94 ± 0.14 ml/ml in the pancreas to 0.16 ± 0.02 ml/ml in the right lung. Estimated boron concentration for 10B-BPA-fr had the highest value in the pancreas (14.0 ± 1.9 ppm 1 h after, and 5.7 ± 1.7 ppm 2 h after the 18F-FBPA administration) and the lowest value in the right lung (2.4 ± 0.3 ppm 1 h, and 1.0 ± 0.3 ppm 2 h post-injection).

CONCLUSION:

The 10B concentration in normal tissues was best estimated using Vt values of 18F-FBPA with the Ichise multilinear analysis 2 (MA2). TRAIL REGISTRY The UMIN clinical trial number UMIN000022850.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Asunto principal: Fenilalanina / Compuestos de Boro / Terapia por Captura de Neutrón de Boro / Neoplasias Tipo de estudio: Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Nucl Med Asunto de la revista: MEDICINA NUCLEAR Año: 2020 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Asunto principal: Fenilalanina / Compuestos de Boro / Terapia por Captura de Neutrón de Boro / Neoplasias Tipo de estudio: Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Nucl Med Asunto de la revista: MEDICINA NUCLEAR Año: 2020 Tipo del documento: Article País de afiliación: Japón